

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Zylox-Tonbridge Medical Technology Co., Ltd.

歸創通橋醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2190)

VOLUNTARY ANNOUNCEMENT THE STRATEGIC INVESTMENT IN WIRE SCIENCES

This announcement is made by the board (the “**Board**”) of directors of Zylox-Tonbridge Medical Technology Co., Ltd. (the “**Company**” or “**Zylox-Tonbridge**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.

The Board is pleased to announce that, in order to promote a standardized, precise and intelligent development of the vascular interventional treatment, and to enhance the Company’s offering for the pan-vascular interventional treatment solution, the Company decided to invest in Wire Sciences Medical Technology (Suzhou) Co., Ltd.* (微亞醫療科技(蘇州)有限公司) (“**Wire Sciences**”, a China-based innovative medical device company and an independent third party of the Company) as a strategic investor, and has recently signed a capital increase agreement with Wire Sciences (the “**Investment**”).

In addition, Zylox-Tonbridge and Wire Sciences have signed a strategic cooperation agreement (the “**Strategic Cooperation Agreement**”). Pursuant to the Strategic Cooperation Agreement, the Company will assist Wire Sciences, by leveraging its own resources and expertise, in its research, development and commercialization process and jointly promote the implementation of the clinical application of the vascular intervention surgical robot. In addition, the Company will have priority access to exclusive distribution rights of the products developed by Wire Sciences in selective regions, to further enrich the Company’s product offering to physicians, patients and hospitals.

* *For identification purpose only*

Wire Sciences is committed to developing comprehensive solutions for interventional surgical robots applied in coronary, intracranial and peripheral blood vessels. Leveraging the Company's strong technology strength and clinical experience, its new and creative technology will improve the efficiency, accuracy, and stability of vascular intervention procedures, and fully fulfill the needs of doctors in intervention procedures. The feasibility of the product has been recognized by leading experts in China.

The Board believes that the strategic investment and cooperation in Wire Sciences will strengthen the Company's leadership position in the field of vascular intervention.

To the best of the knowledge, information and belief of the Board having made all reasonable enquiries, Wire Sciences and its ultimate beneficial owners are third parties independent of the Company and its connected persons (as defined under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") , as amended from time to time), and the Investment and the transactions contemplated under the Strategic Cooperation Agreement do not constitute a notifiable transaction of the Company under Chapter 14 of the Listing Rules.

By order of the Board
Zylox-Tonbridge Medical Technology Co., Ltd.
Dr. Jonathon Zhong Zhao
Chairman and Executive Director

Hong Kong, January 17, 2022

As of the date of this announcement, the Board comprises Dr. Jonathon Zhong Zhao, Mr. Yang Xie and Dr. Zheng Li as executive Directors, Mr. Stephen Hui Wang, Dr. Hai Lu and Dr. Steven Dasong Wang as non-executive Directors, and Dr. Jian Ji, Mr. Hongze Liang and Ms. Yun Qiu as independent non-executive Directors.